The scientific programme will feature themed lectures, focusing on medicinal chemistry and related technologies and disciplines across a range of drug targets and modalities. A distinguishing feature of this symposium is the collegiate style, which encourages an atmosphere of information sharing and learning.
Stop by our exhibit table and have a chat with Renate Baker and Susana Tomasio from CDD about your discovery informatics workflows.
The Drug Discovery Summit is an invaluable resource for those looking to improve efficiency, increase pipelines, and keep up-to-date with the latest advances.
Looking at small molecules and biologics, this congress will feature key insights into protein degradation, AI/ML in drug discovery, and provide updates in screening and modeling, including CRISPR and organ-on-a-chip techniques. Key therapeutic areas include immunotherapy and oncology.
You guessed it… there’s a special CDD Vault ELN bonus included with this look-up feature! The “Insert Compound or Reaction” button (found in the header of your ELN entries) will also look up these same Molecule IDs, Synonyms, Common Names, or CAS Numbers and insert these objects’ structures directly into your ELN entry.
Note: You might attempt to look up external items that cannot be rendered at this time. But rest assured, the repository of Common Names and CAS Numbers available for look-up will be expanded over time.
Be sure to contact CDD Support – we are always available to help you be more successful with CDD Vault!
Jubilant Biosys Selects CDD Vault to Communicate Research Data With Customers for Next Five Years
CDD Vault to support Jubilant networked research to advance the collaborative experience with their customers
Jubilant Biosys Selects CDD Vault to Communicate Research Data with Customers for Next Five Years
NOIDA, India and BURLINGAME, California, May 8, 2019 /PRNewswire/ --Jubilant Biosys and Collaborative Drug Discovery (CDD) announced today, following an exhaustive evaluation, Jubilant has chosen CDD Vault as their discovery research informatics platform for the next 5 years. Jubilant will be using CDD Vault as their informatics platform to facilitate and boost transparent distribution of research data and information. CDD Vault manages biological assay data, involved chemical structures, reactions and compound properties in a cohesive environment.
"CDD Vault will be used across Jubilant research sites; to keep experimental information centralized, both structured and unstructured, to share with clients," said Marcel Velterop, President of Drug Discovery Services & CDMO at Jubilant Biosys Limited. "Scientists will be able to explore their chemistry and biology data in real-time, enabling rapid decision-making of discovery programs with CDD Vault."
"Jubilant is a leading collaborator for pharmaceutical and biotechnology companies worldwide and we are delighted to assist them in sharing their high quality preclinical R&D services with the life science industry," said Dr. Mariana Vaschetto, General Manager, CDD Global Business. "CDD Vault has been designed for collaborative research within or between organizations in a secure and easy to use way. We are looking forward to this long term relationship with Jubilant and helping them ensure the success of their customers' research."
CDD's flagship product, 'CDD Vault®', is used to manage chemical registration, structure activity relationships (SAR) and securely scale collaborations. CDD Vault®, a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data and collaborate with internal or external partners through an easy-to-use web interface. Available modules include Activity & Registration, Visualization, Inventory and ELN.
About Jubilant Biosys Limited
Jubilant Biosys, a subsidiary of Jubilant Life Sciences Ltd., is an integrated global pharmaceutical and life sciences company, has presence in Bengaluru and Noida in India. Jubilant Biosys has demonstrated expertise across multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation and CNS. Business models include both functional and integrated discovery services up to IND including GLP as well as Phase 1/2 GMP supplies, as core components which are available for collaborative research.
Thursday, June 13, 2019 • 9:00 AM PT • 12:00 PM ET • 17:00 GMT
One of the most important assets in science is data, but how valuable is that data if we don't understand the metadata behind it? A point on a graph, a static image of a cell, or a readout from an instrument mean nothing without the experimental details that characterize them.
Today, accurate metadata capture is being recognized as a means to increase reproducibility and productivity across the scientific community. Initiatives like GO FAIR seek to make data Findable, Accessible, Interoperable, and Reusable and are increasing in popularity.
Metadata can greatly augment scientific data. In practice, we must ensure that metadata capture does not become a burden to the scientist.
Collaborative Drug Discovery set out to design a simple, quick, and efficient method of assay metadata management. We developed BioAssay Express (BAE) to do just that — our smart tool incorporates a hybrid machine-learning approach with expertly curated ontologies to unambiguously annotate your assay metadata with ease. It also provides a powerful engine for searching, comparing, and analyzing your assays. Assay Annotations have also been implemented into CDD Vault for Assay Registration.
Please join our expert panel of scientists, Dr. Ellen Berg (Eurofins and Alto Predict) and Dr. Isabella Feierberg (AstraZeneca) as they discuss the importance of metadata and their vision for how assay annotation will shape the future of drug discovery.
Click the button below to register now for this webinar coming up on Thursday, March 14th at 9:00 AM PT, noon ET, and 17:00 GMT.
Ellen L. BergChief Scientific Officer, Translational Biology for Eurofins Discovery
Ellen L. Berg, PhD is an entrepreneur and scientific leader in drug discovery technology innovation.
She is Chief Scientific Officer, Translational Biology for Eurofins Discovery and a principal at Alto Predict LLC. Dr.
Berg was the lead inventor of the BioMAP® platform of human primary cell-based disease models, now successfully commercialized by Eurofins and serving the pharmaceutical and consumer products industries to deliver safer and more effective products.
In previous positions, Dr. Berg was co-founder and CSO of BioSeek, Inc. and led a research team at Protein Design Labs, Inc.
She received her PhD from Northwestern University and was a postdoctoral fellow at Stanford University, where she was a fellow of the American Cancer Society and a Special Fellow of the Leukemia Society of America.
She is currently focused on working with industry, academic, and government stakeholders to incorporate non-animal, human-based in vitro and in silico predictive models into the drug discovery process and helping to promote the adoption of these platforms by regulatory agencies.
Dr. Berg holds several patents in the field of inflammation, and has authored over 80 publications.
Isabella FeierbergAssociate Principal Scientist, AstraZeneca
Isabella Feierberg, PhD has over 20 years of experience as a computational chemist in the early drug discovery field.
Her expertise in small molecule library design, HTS analysis, assay development, and assay informatics has led the way to a passion for FAIR (Findable, Accessible, Interoperable, and Reusable) data.
Isabella is currently working with the Pistoia Alliance to implement a crowd-sourced project that would curate public domain assay protocols with ontologies to provide high-quality metadata.
Dr. Feierberg received her MSc Eng and PhD from Uppsala University.
WE'RE ALWAYS HERE TO HELP!
Know that CDD Support is here to help you reference CDD Vault in your talks, posters, or other presentations. Contact us if you want assistance with:
CDD Vault Celebrates 1 Millionth User Login with R2M Pharma
Dr. Tien Widjaja is the lucky, one-millionth user to login to CDD Vault.
When Dr. Tien Widjaja logged into CDD Vault for the first time in April 2018, she had no idea that she would score the lucky one millionth user login to the system just a year later.
“CDD Vault has been a valuable data management tool and it feels good to be part of this milestone,” says Tien, a Scientist in the medicinal chemistry group at R2M Pharma Inc (R2M).
Based in California, R2M’s mission is to accelerate drug discovery by taking drug candidates from early hit stage all the way to phase 1 clinical trial. The company prides itself in providing timely and cost-effective compound optimization service for its many external clients, in addition to having several internal projects. To do that, R2M needed a digital platform that could not only easily store and share data with external collaborators, but also protect the security of its own data. CDD Vault turned out to be the perfect solution.
“What I really like about the Vault,” says Julio Medina, PhD, CEO of R2M, “is that it enables us to share data in real-time with multiple partners, across diverse projects, while maintaining control of exactly who is able to access what information, which instills confidence in our partners.”
CDD Vault provides a centralized platform where R2M stores multiple types of data, including molecule registration, chemical and biological data, and experiment documentation using the ELN module. Not only does this safeguard against data loss, it’s also a time-saver when it comes to patent filing and sharing procedures, because everything is already captured electronically. In fact, some of R2M’s clients were so impressed with CDD Vault that they went on to obtain their own Vaults.
“CDD Vault has been hosting customer data for 15 years and the one-millionth login is a reflection of our super loyal customers,” according to Barry Bunin, PhD, CEO of Collaborative Drug Discovery. “We are proud to support the important research of forward-leaning scientists like Dr. Tien Widjaja at R2M.”
Historically, spring was a hallmark season for new trails and new adventures. In the 1800s, American pioneers emigrated westward following the Oregon Trail. These pioneers embarked on their journeys during the Spring in order to reach Oregon before the winter snows made travel impossible.
Keeping with this tradition, CDD is announcing a trail of our own… the ELN Audit Trail!
ELN Audit Trail
The CDD Vault Electronic Lab Notebook includes an audit trail of users’ activities within their ELN entries. This provides a record of major events organized in reverse-chronological order, including the user, timestamp, and a description for each event.
To see the Audit Trail, select the “Audit Trail” button found in the header of your ELN entry.